John McIlwraith - 31 Jan 2023 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC

Reporting relationship
Director
Issuer ticker
N/A
Reported as of
31 Jan 2023
Net transaction value
-$1,392,681
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
31 Jan 2023, 13:19:09 UTC
Prior SEC filing
28 Jan 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ F. Mark Reuter as Attorney-in-Fact for John McIlwraith

Key filing fact

John McIlwraith filed Form 4 for MERIDIAN BIOSCIENCE INC on 31 Jan 2023.

Key facts

  • This page summarizes John McIlwraith's Form 4 filing for MERIDIAN BIOSCIENCE INC.
  • 9 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 31 Jan 2023, 13:19.

Change

  • Previous filing in this sequence was filed on 28 Jan 2022.
  • Current net transaction value: -$1,392,681.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIVO transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-21,724
Change %
-100%
Price
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$134,470
Shares
-8,500
Change %
-100%
Price
$15.82
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,500
Exercise price
$18.18
Footnotes
F2
VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$130,560
Shares
-8,500
Change %
-100%
Price
$15.36
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,500
Exercise price
$18.64
Footnotes
F3
VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$212,000
Shares
-10,000
Change %
-100%
Price
$21.20
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$12.80
Footnotes
F4
VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$213,600
Shares
-12,000
Change %
-100%
Price
$17.80
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,000
Exercise price
$16.20
Footnotes
F5
VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$148,842
Shares
-8,740
Change %
-100%
Price
$17.03
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,740
Exercise price
$16.97
Footnotes
F6
VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$405,006
Shares
-17,205
Change %
-100%
Price
$23.54
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,205
Exercise price
$10.46
Footnotes
F7
VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$73,261
Shares
-5,796
Change %
-100%
Price
$12.64
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,796
Exercise price
$21.36
Footnotes
F8
VIVO transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$74,942
Shares
-5,656
Change %
-100%
Price
$13.25
Shares after
0
Date
31 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,656
Exercise price
$20.75
Footnotes
F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

John McIlwraith is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 9 footnotes

Footnote F1

The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.

Footnote F2

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

Footnote F3

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

Footnote F4

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

Footnote F5

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

Footnote F6

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

Footnote F7

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

Footnote F8

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

Footnote F9

The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .